PriceTargets.com logo

Medacta Group - MEDGF Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$83.91 As of 04/15/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for MEDGF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medacta Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MEDGF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MEDGF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Medacta Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $83.91.

This chart shows the closing price for MEDGF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in Medacta Group. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/20/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight
10/18/2022Morgan StanleyInitiated CoverageOverweight
9/26/2022Credit Suisse GroupLower TargetOutperform ➝ OutperformCHF 120 ➝ CHF 105
7/20/2022UBS GroupLower TargetBuy ➝ BuyCHF 135 ➝ CHF 119
7/8/2022JPMorgan Chase & Co.Lower TargetCHF 124 ➝ CHF 100
6/16/2022Credit Suisse GroupLower TargetCHF 132 ➝ CHF 125
4/27/2022UBS GroupUpgradeNeutral ➝ Buy
4/27/2022Credit Suisse GroupUpgradeNeutral ➝ Outperform
3/14/2022JPMorgan Chase & Co.Lower TargetCHF 152 ➝ CHF 124
11/12/2021JPMorgan Chase & Co.Reiterated RatingNeutral
9/30/2021UBS GroupReiterated RatingNeutral
6/9/2021Credit Suisse GroupDowngradeOutperform ➝ Neutral
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Medacta Group logo
Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine procedures. Medacta Group SA was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.
Read More

Today's Range

Now: $83.91
Low: $83.91
High: $83.91

50 Day Range

MA: $83.91
Low: $83.91
High: $83.91

52 Week Range

Now: $83.91
Low: $83.91
High: $86.33

Volume

1 shs

Average Volume

200 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Medacta Group?

The following Wall Street research analysts have issued stock ratings on Medacta Group in the last twelve months: Morgan Stanley.
View the latest analyst ratings for MEDGF.

What is the current price target for Medacta Group?

0 Wall Street analysts have set twelve-month price targets for Medacta Group in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Medacta Group in the next year.
View the latest price targets for MEDGF.

What is the current consensus analyst rating for Medacta Group?

Medacta Group currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MEDGF, but not buy more shares or sell existing shares.
View the latest ratings for MEDGF.

What other companies compete with Medacta Group?

Other companies that are similar to Medacta Group include Ainos, Avitar, BICO Group AB (publ), Bone Biologics and Caliber Imaging & Diagnostics. Learn More about companies similar to Medacta Group.

How do I contact Medacta Group's investor relations team?

Medacta Group's physical mailing address is Strada Regina, Castel San Pietro, Ticino (Ticiono). The company's listed phone number is 41 91 696 60 60. The official website for Medacta Group is www.medacta.com. Learn More about contacing Medacta Group investor relations.